Business Wire

OCTASIC-INC

Share
Panasonic and Octasic Extend sXGP Collaboration to 5G/Beyond 5G

Panasonic Corporation, a world-leading provider of diverse electronics technologies, B2B, communications and wireless solutions, and Octasic Inc., an innovation leader in low-power programmable processors for wireless and multimedia applications, today announced the enhancement of their ongoing collaboration to develop shared eXtended Global Platform (sXGP) solutions to include 5G and Beyond 5G based wireless network products, especially for mission-critical applications.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005982/en/

Panasonic and Octasic will combine resources and expertise to develop high-performance, high reliability, and low-latency Small Cell solutions for the cellular IoT space, applied to B2B, Non-Terrestrial Networks in Avionics and other mission-critical verticals based on Octasic's OCT3032 System-on-Chip.

The Collaboration on sXGP

Panasonic has developed an sXGP wireless base station that makes full use of the OCT3032's embedded Opus DSP technology and realizes stable communication even in environments with high interference in unlicensed bands.

The 5G Collaboration

The expanded collaboration addresses the challenging requirements of developing a new class of Small Cells to be deployed in a wireless base station platform that contributes to mission-critical applications for advanced IoT environments and non-terrestrial operations toward 5G and Beyond 5G.

Octasic’s programmable processor platform delivers on the low power requirements of Panasonic Small Cell designs and accelerates development and support of multiple air interfaces from sXGP to 3GPP. More importantly it addresses the need for deterministic air interface design to meet the challenges of implementing an ultra-reliable low-latency solution in diverse environments from private campus-wide networks, to machine or robotic communication in warehouses, to aircraft systems.

Panasonic promotes the development of Ultra-Reliable and Low-Latency Communications (URLLC) functions that comply with both 3GPP and Non-Terrestrial Network (NTN) technologies and provides Octasic with engineering expertise and resources. In addition, Panasonic will accelerate digital transformation for itself and its customers demonstrating various IoT-related applications inside and outside the company.

Hideo Ohara, Director of Panasonic Technology Department, emphasized, “We are leveraging Octasic’s OCT3032 System-on-Chip, development tools, and 4G/5G software to develop and deploy differentiated sXGP, 4G, and 5G Small Cell network products that deliver on our world-leading technical requirements for high performance, highly reliable, low latency, and low power Small Cell network products. We are delighted to advance the evolution of society with such unique systems that are the culmination of our years of technological collaboration with Octasic.”

Fabio Gambacorta, Global VP Business Development and Sales at Octasic emphasized, “Offering a world-leading System-on-Chip solution for Small Cell designs does not happen by chance; it is critical to partner with an innovative wireless network OEM like Panasonic. Octasic is proud to collaborate on not only the development of Panasonic’s first sXGP network products, but to expand this collaboration to encompass future solutions for 3GPP-compliant 4G and 5G networks, especially those requiring high reliability, low latency, and low power.”

For more information about the OCT3032 SoC and its evaluation and development platforms, please contact pr@octasic.com or visit www.octasic.com/product/oct3032w/ .

About Octasic Inc.

Founded in 1998 and headquartered in Canada, Octasic develops innovative programmable processors for mobile wireless markets such as proprietary 4G/5G-based networks. Octasic’s Opus-based processor technology, programming tools, software and reference code reduce costs, mitigate risk, accelerate time-to-market, and allow developers to focus engineering resources on their areas of differentiation. With 20 years of technology development in low-power programmable System-on-Chip solutions, Octasic products deliver a low-power, low-latency “5G Small Cell on a Chip” for both commercial and private networks. For more information, please visit http://www.octasic.com/ .

About Panasonic Corporation

Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 72 associated companies worldwide, recording consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global .

For media inquiries, please contact Global Communications Department:

https://news.panasonic.com/global/contacts/

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release

The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release

Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release

SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye